Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: GlobalData
$250.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Atcor Medical Holdings Ltd Receives FDA Clearance for SphygmoCor XCEL


Tuesday, 27 Nov 2012 09:05am EST 

Atcor Medical Holdings Ltd announced that it had received 510(k) marketing clearance from the US Food and Drug Administration (FDA) for its SphygmoCor XCEL device. SphygmoCor XCEL, is a new blood pressure cuff- based system that allows brachial and central aortic blood pressure to be measured quickly and simply. With the new system, traditional brachial blood pressure measurement and pulse wave analysis, which measures central aortic pressure, can be performed quickly and easily. The SphygmoCor XCEL system also provides a simpler and more convenient method of performing pulse wave velocity measurement, a test used to measure aortic stiffness. 

Company Quote

0.092
-0.0020 -2.13%
29 Sep 2014